News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
24,893 Results
Type
Article (3617)
Company Profile (4)
Press Release (21272)
Multimedia
Podcasts (15)
Webinars (3)
Section
Business (8673)
Career Advice (39)
Deals (1209)
Drug Delivery (19)
Drug Development (4333)
Employer Resources (12)
FDA (700)
Job Trends (1061)
News (14643)
Policy (1522)
Tag
2024 Biotech Bay Standard (1)
Academia (80)
Adcomms (1)
Allergies (1)
Alliances (2270)
ALS (2)
Alzheimer's disease (28)
Antibody-drug conjugate (ADC) (32)
Approvals (697)
Artificial intelligence (12)
Autoimmune disease (1)
Bankruptcy (9)
Best Places to Work (846)
BIOSECURE Act (7)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (8)
Brain cancer (6)
Breast cancer (25)
Cancer (221)
Cardiovascular disease (14)
Career advice (38)
Career pathing (1)
CAR-T (6)
Cell therapy (14)
Cervical cancer (5)
Clinical research (3550)
Collaboration (36)
Compensation (2)
Complete response letters (4)
COVID-19 (199)
CRISPR (1)
C-suite (14)
Cystic fibrosis (2)
Data (62)
Depression (2)
Diabetes (2)
Diagnostics (90)
Diversity, equity & inclusion (2)
Drug discovery (7)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (4)
Earnings (2159)
Editorial (6)
Employer branding (6)
Employer resources (11)
Events (2338)
Executive appointments (59)
FDA (721)
Featured Employer (1)
Funding (17)
Gene editing (5)
Generative AI (2)
Gene therapy (7)
GLP-1 (67)
Government (284)
Grass and pollen (1)
Guidances (2)
Healthcare (482)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (11)
Indications (1)
Infectious disease (207)
Inflammatory bowel disease (6)
Inflation Reduction Act (3)
Intellectual property (4)
Interviews (2)
IPO (367)
IRA (12)
Job creations (284)
Job search strategy (36)
Kidney cancer (3)
Layoffs (43)
Legal (401)
Liver cancer (7)
Lung cancer (58)
Lymphoma (6)
Machine learning (1)
Management (4)
Manufacturing (22)
MASH (3)
Medical device (82)
Medtech (82)
Mergers & acquisitions (851)
Metabolic disorders (19)
Multiple sclerosis (5)
Neurodegenerative disease (5)
Neuropsychiatric disorders (2)
Neuroscience (45)
NextGen: Class of 2025 (195)
Non-profit (90)
Northern California (55)
Obesity (12)
Opinion (34)
Ovarian cancer (6)
Pain (2)
Pancreatic cancer (3)
Parkinson's disease (2)
Patents (12)
Patient recruitment (2)
People (3795)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase I (1043)
Phase II (1613)
Phase III (1465)
Pipeline (55)
Policy (31)
Postmarket research (201)
Preclinical (266)
Press Release (2)
Prostate cancer (4)
Psychedelics (2)
Radiopharmaceuticals (16)
Rare diseases (8)
Real estate (212)
Recruiting (4)
Regulatory (962)
Reports (7)
Research institute (71)
Resumes & cover letters (1)
RSV (7)
Schizophrenia (2)
Series A (5)
Series B (5)
Sickle cell disease (2)
Southern California (38)
Special edition (3)
Spinal muscular atrophy (3)
Sponsored (2)
Startups (206)
Stomach cancer (8)
Supply chain (5)
Tariffs (10)
The Weekly (13)
United States (538)
Vaccines (101)
Venture capitalists (4)
Weight loss (16)
Women's health (1)
Worklife (1)
Date
Today (3)
Last 7 days (16)
Last 30 days (78)
Last 365 days (1152)
2025 (293)
2024 (1237)
2023 (1319)
2022 (2976)
2021 (2787)
2020 (2293)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1327)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (64)
Alabama (3)
Alaska (1)
Arizona (2)
Asia (1428)
Australia (379)
California (110)
Canada (55)
China (29)
Colorado (2)
Connecticut (2)
Delaware (9)
Europe (4285)
Florida (26)
Illinois (3)
Indiana (1)
Japan (20)
Maryland (12)
Massachusetts (129)
Minnesota (2)
Missouri (2)
Nevada (1)
New Hampshire (2)
New Jersey (120)
New York (55)
North Carolina (10)
Northern California (55)
Ohio (1)
Oregon (1)
Pennsylvania (13)
Rhode Island (2)
South America (61)
Southern California (38)
Texas (15)
Utah (5)
Virginia (1)
Washington D.C. (5)
Washington State (24)
24,893 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Merck KGaA Fails Phase III Study in Head and Neck Cancer, Scraps Trials
Merck KGaA’s drug candidate xevinapant in a late-stage trial was unable to significantly improve event-free survival in patients with locally advanced head and neck cancer.
June 25, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany
February 28, 2025
·
6 min read
Cancer
Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
BioMidwest
Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million
Gamma Biosciences announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
May 23, 2024
·
4 min read
Press Releases
Merck KGaA, Darmstadt, Germany Announces Launch of Caregiver Leave Benefit, Strengthening Inclusive Family-Friendly Offerings
January 22, 2025
·
4 min read
Press Releases
Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
January 9, 2025
·
5 min read
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.
April 1, 2025
·
2 min read
·
Tristan Manalac
Business
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it has entered into a multi-target drug discovery collaboration with Merck KGaA, Darmstadt, Germany.
June 3, 2024
·
2 min read
Drug Development
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
June 24, 2024
·
4 min read
1 of 2,490
Next
